It is for the reason of angiogenesis that VEGF have a clear relationship with UGIB and could be view as a marker to assess the risk of perioperative bleeding in gastric cancer.[16–19] So cetuximab could reduce the protective and renewal ability of mucosa and vessels, and increase the possibility of GI damage and hemorrhage to some extent. This evidence concerns the gene VEGFA and gastric cancer.